Cibc Asset Management Has Cut P T Telekomunikasi Indonesia (TLK) Stake By $410,520; Alnylam Pharmaceuticals (ALNY) Sentiment Is 1.52

November 25, 2017 - By Vivian Park

Cibc Asset Management Inc decreased P T Telekomunikasi Indonesia (TLK) stake by 5.21% reported in 2017Q2 SEC filing. Cibc Asset Management Inc sold 12,440 shares as P T Telekomunikasi Indonesia (TLK)’s stock rose 18.87%. The Cibc Asset Management Inc holds 226,195 shares with $7.62 million value, down from 238,635 last quarter. P T Telekomunikasi Indonesia now has $33.01 billion valuation. The stock increased 2.28% or $0.71 on November 24, reaching $31.8. About 235,931 shares traded. Telekomnks Indn Prsr Tbk Prshn Prsrn-ADR (NYSE:TLK) has risen 27.32% since November 25, 2016 and is uptrending. It has outperformed by 10.62% the S&P500.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $13.06 billion. The Firm is engaged in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Ratings analysis reveals 57% of Alnylam Pharma’s analysts are positive. Out of 7 Wall Street analysts rating Alnylam Pharma, 4 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $36.0 while the high is $137.0. The stock’s average target of $87.50 is -34.14% below today’s ($132.85) share price. ALNY was included in 7 notes of analysts from October 6, 2016. The firm has “Buy” rating given on Thursday, October 6 by Chardan Capital Markets. The rating was maintained by FBR Capital with “Outperform” on Thursday, October 6. The rating was downgraded by Leerink Swann on Thursday, October 6 to “Mkt Perform”. Needham maintained the stock with “Buy” rating in Thursday, October 6 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Thursday, February 2 by Ladenburg Thalmann. JP Morgan downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, October 6 to “Neutral” rating. The firm has “Hold” rating given on Thursday, October 6 by Stifel Nicolaus.

The stock increased 0.39% or $0.52 on November 24, reaching $132.85. About 783,126 shares traded. Alnylam Pharmaceuticals, Inc. (ALNY) has risen 33.54% since November 25, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

12 West Capital Management Lp holds 9.45% of its portfolio in Alnylam Pharmaceuticals, Inc. for 700,000 shares. Perceptive Advisors Llc owns 1.83 million shares or 7.36% of their US portfolio. Moreover, Fic Capital Inc has 5.59% invested in the company for 170,329 shares. The Connecticut-based Great Point Partners Llc has invested 3.96% in the stock. Opus Point Partners Management Llc, a New York-based fund reported 49,095 shares.

Since January 1, 0001, it had 2 buys, and 0 sales for $22.13 million activity.